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Abstract
Alzheimer’s disease (AD) affects an estimated 44 million individuals worldwide, yet no 
therapeutic intervention is available to stop the progression of the dementia. Neuropathological 
hallmarks of AD are extracellular deposits of amyloid beta (Aβ) peptides into plaques, 
intraneuronal accumulation of hyperphosphorylated tau protein forming tangles, and chronic 
inflammation. A pivotal molecule in inflammation is the pro-inflammatory cytokine TNF-α. 
Several lines of evidence using genetic and pharmacological manipulations indicate that TNF-α 
signaling exacerbates both Aβ and tau pathologies in vivo. Interestingly, preventive and 
intervention anti-inflammatory strategies demonstrated a reduction in brain pathology and an 
amelioration of cognitive function in rodent models of AD. Phase I and IIa clinical trials suggest 
that TNF-α inhibitors might slow down cognitive decline and improve daily activities in AD 
patients. In the present review, we summarize the evidence pointing towards a beneficial role of 
anti-TNF-α therapies to prevent or slow the progression of AD. We also present possible physical 
and pharmacological interventions to modulate TNF-α signaling in AD subjects along with their 
limitations.
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1. INTRODUCTION
Alzheimer’s disease (AD) is the most prominent form of dementia worldwide, affecting an 
estimated 44 million people [1]. Patients progressively become debilitated, placing a heavy 
emotional and financial burden on caregivers and healthcare systems [1]. 
Neuropathologically, AD is characterized by 1- the extracellular accumulation of amyloid 
beta (Aβ) oligomers and other materials into dense senile plaques; 2- the intraneuronal 
hyperphosphorylation of the microtubule-binding protein tau which induces its aggregation 
into tangles; and 3- chronic inflammation [2]. Together, these events disrupt the homeostatic 
functioning of neurons by affecting synaptic transmission and intracellular transport, 
ultimately leading to neuronal death. Amyloid beta is generated via the consecutive 
proteolysis of the amyloid precursor protein (APP) by β- and γ-secretases. The main β-
secretase in AD was identified as beta amyloid converting enzyme 1 (BACE1) [3]. Gamma 
secretase is a tetramer comprising presenilin 1 or 2 (PSEN1/2), anterior pharynx-defective 1 
(APH-1), nicastrin (NCT), and presenilin enhancer 2 (PEN-2) [4].
Following its discovery in 1984 [5], Aβ was found to be a hallmark of AD- and Down 
syndrome-associated brain plaques [6]. These observations seeded the formulation of the 
amyloid cascade hypothesis which describes Aβ as the central cause of AD neuropathology 
[7, 8]. Based on this hypothesis, blocking amyloidogenesis or preventing Aβ aggregation 
should lower brain Aβ loads and plaque formation, and thus improve cognition in AD 
subjects. Different strategies have been tested in clinical trials, including 1- BACE1 
inhibitors [9]; 2- γ-secretase inhibitors and modulators [10]; and 3- active and passive 
immunization targeting monomeric, oligomeric, and protofibril Aβ [11]. However, all trials 
completed to date have failed to meet the clinical end-points of significantly improving the 
cognition and daily living functions of AD patients. Furthermore, although bio-marker and 
post-mortem analyses suggest target engagement as identified by lower brain and CSF Aβ 
loads [12–14], most trials reported substantial adverse events, such as unexpected liver 
toxicity for the BACE1 inhibitor LY2886721 [15], weight loss and skin cancers for γ-
secretase inhibitors [16], and microhemorrhages, vasogenic edema, and meningoencephalitis 
for Aβ immunization [11, 17], sometimes leading to early termination of the trials. These 
results, combined with observations of elevated brain Aβ42 in aged, non-demented 
individuals with cerebral atherosclerosis [18], and the lack of correlation between dementia 
progression and brain Aβ levels [19] are feeding the debate about the validity of the amyloid 
cascade hypothesis (for recent discussions see [20–22]), and prompting the investigation of 
additional targets and methods for therapeutic interventions.
An alternative approach to Aβ modulation is immunization against hyperphosphorylated tau 
[23]. For example, following an encouraging Phase I study AXON Neuroscience is starting a 
Phase II trial with its AADVAC1 vaccine [24, 25].
Another possible strategy is the use of anti-inflammatory agents. A growing body of 
evidence implicates proinflammatory cytokines as enhancers of Aβ and tau pathologies (see 
section 3 below) [26, 27]. Several epidemiological studies suggest a sparing of AD in 
individuals taking non-steroidal anti-inflammatory drugs (NSAIDs) for at least two years 
prior to symptom onset (reviewed in [22]). NSAIDs are non-selective inhibitors of 
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cyclooxygenase-1 (COX-1) and COX-2. However, clinical trials did not corroborate these 
epidemiological findings [28]. A possible explanation for the latter result is that the cohorts 
treated during clinical trials were already suffering AD while epidemiological studies 
suggest a preventive action of NSAIDs on presymptomatic individuals. Nonetheless, further 
studies found no AD prevention effect by COX-2 specific inhibitors [22]. To note, NSAIDs 
are known to induce gastrointestinal and kidney adverse events [29], which limit enthusiasm 
for their chronic use on AD patients.
Aged-related changes in the immune system, known as immunosenescence, and increased 
secretion of cytokines by adipose tissue represent the major causes of chronic inflammation 
during aging. This phenomenon is known as “in-flamm-aging” [30]. A major pro-
inflammatory molecule involved in neurological disorders, including AD, is tumor necrosis 
factor alpha (TNF-α) [30–33]. Anti-TNF-α interventions have been proposed to modulate 
AD neuropathology, and current data suggests it may also improve cognitive function (see 
section 4 below). In the present article we review the reasons behind targeting TNF-α for 
AD treatment and list several options to lower TNF-α, along with their potential challenges.
2. THE BIOLOGY OF TNF-α IN THE CENTRAL NERVOUS SYSTEM
TNF-α and its receptors regulate a plethora of physiological functions in the body, including 
immune surveillance, immune reactions to fight microbial infections, induction of cell death, 
for example to eliminate cancer cells or in pathological conditions like allergies [34–37]. In 
this section we provide a summary of TNF-α expression, signaling pathways, and 
physiological roles in the central nervous system (CNS).
2.1. TNF-α Expression
TNF-α controls numerous physiological processes in the CNS [34]. Therefore, it is not 
surprising that its expression is tightly regulated at the transcriptional, post-transcriptional, 
and translational levels to maintain homeostasis. The TNF-α gene is located within the 
Major Histocompatibility Complex (MHC) II region on the short arm of chromosome 6, and 
comprises four exons and three introns. A variety of transcription factors can bind and 
activate the TNF-α promoter, including NF-κβ, CCAAT/enhancer binding protein β (C/
EBPβ), SP-1, Erg-1, and c-Jun (summarized in [32]). TNF-α protein is synthesized as a type 
II transmembrane protein (tmTNF-α) of 26 kDa [38]. The metalloprotease TNF-α 
converting enzyme (TACE/ADAM17) can shed tmTNF-α from the plasma membrane and 
release a soluble form (sTNF-α) of 17 kDa into the extracellular milieu [39]. Interestingly, 
both tmTNF-α and sTNF-α assemble in homotrimers that are biologically active when 
engaging TNF-α receptors [32].
2.2. TNF-α Signaling
TNF-α exerts its actions by binding two distinct type I, high-affinity receptors located at the 
cell surface. TNF-RI (p55 or p60) is ubiquitously and constitutively expressed, except on 
erythrocytes, while TNF-RII (p75 or p80) expression is restricted to myeloid cells, 
endothelial cells, myocytes, thymocytes, oligodendrocytes, microglia, astrocytes, and sub-
populations of neurons (summarized in [40, 41]). TNF-RI binds equally well with the sTNF-
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α and the tmTNF-α, however TNF-RII preferentially binds to the tmTNF-α [42]. 
Historically, the two receptors were ascribed antagonistic effects with TNF-RI being pro-
apoptotic and TNF-RII playing a protective role. However, recent studies have shown that 
both receptors are capable of driving cell survival and cytotoxicity depending on age, 
extracellular TNF-α levels, the cell type expressing the receptors, and intracellular signaling 
pathways activated by other trophic factors (reviewed in [32,33]). TNF receptors mediate 
signals via the recruitment and inhibition of adapter proteins (for details see [32, 33]). 
Briefly, both receptors share similar signaling cascades that activate the mitogen-activated 
protein kinase (p38 MPAK), c-jun N-terminal kinase (JNK), extracellular-signal-regulated 
kinases (ERKs), acid sphingomyelinase (A-SMase), neutral sphingomyelinase (N-SMase) 
pathways, and the transcription factors AP-1 and NF-κB, which then induce the expression 
of molecules participating in inflammation and amyloidogenesis [32, 42, 43]. Interestingly, 
tmTNF-α is capable of reverse signaling, i.e. when tmTNF-α (or an agonist/antagonist) 
binds to its receptor it can increase intracellular calcium levels (in the cell bearing tmTNF-
α), which activates p38 MAPK, upregulates NF-κB signaling, and induces cell survival or 
death [44].
2.3. Sources of TNF-α and Its Roles in the Central Nervous System
In order to target TNF-α for AD treatment it is important to identify the cells expressing this 
pro-inflammatory cytokine in the CNS. In the past three decades, an increasing number of 
physiological and deleterious functions have been credited to TNF-α signaling in the CNS 
[32, 45, 46]. A non-exhaustive list of TNF-α roles in the CNS is provided in Table 1. Since 
TNF-α signaling stimulates NF-κB, many (though not all) of the functions attributed to 
TNF-α in the CNS are also controlled by NF-κB signaling (see recent reviews [47, 48] for 
details).
Numerous studies have shown that TNF-α is expressed at physiological levels by microglia 
and neurons; but its expression increases in activated microglia, neurons, oligodendrocytes, 
reactive astrocytes, epithelial cells, endothelial cells, and ependymal cells upon brain and 
peripheral injuries, and in chronic disorders [49–51]. Moreover, like other cytokines [52, 
53], TNF-α can cross the intact blood brain barrier (BBB) via transcytosis involving both 
TNF-RI and TNF-RII [54], and affect cognitive functions [55]. In addition, peripheral 
immunocompetent cells that produce TNF-α may migrate across the BBB to enter the brain 
parenchyma and cerebrospinal fluid (CSF) [56]. In aggregate, these findings suggest that 
several central and peripheral sources of TNF-α may contribute to AD neuropathology (see 
section 3 below) [57], although it is still unclear which source of TNF-α seeds chronic 
neuroinflammatory reactions.
3.TNF-α IN ALZHEIMER’S DISEASE
3.1. TNF-α Levels in Alzheimer’s Disease
Numerous studies have described elevated TNF-α levels in biological fluids in aging, mild 
cognitive impairment (MCI) and in AD patients (meta-analysis conducted in [77]). Early 
reports indicated that TNF-α levels are elevated in the CSF of AD patients compared to 
cognitively normal controls (e.g. [78]). However, a recent meta-analysis did not find a 
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significant difference between the two populations of patients [79]. From recent discussions 
[80] and our own experience, we hypothesize that part of the controversy might originate 
from the lack of standardization for sample collection, and the very low concentration of 
TNF-α in biological fluids (e.g. serum values ranging 0–4 pg/mL in healthy subjects), which 
likely impedes reproducible measurements across study centers. Nevertheless, it is widely 
accepted that TNF-α plasma levels are higher in MCI and AD vs. cognitively normal 
individuals [79, 81]. Importantly, both TNF-α and TNF-RI levels were shown to be 
increased in the postmortem brain of early-stage AD patients [82]. Furthermore, challenging 
primary cultures of rodent and human microglial cells with Aβ induces the release of high 
levels of TNF-α [83–85]. In addition, in a recent study human TNF-α cDNA flanked with a 
human cytomegalovirus promoter was delivered to the hippocampal CA1 region via an 
adeno-associated virus in 2 month-old 3xTg-AD mice (pre-pathological stage) for specific 
overexpression of TNF-α in neurons [86]. This manipulation induced the activation of 
microglia and neuronal death, revealing that TNF-α-driven inflammation may have a 
deleterious effect on neurons [86]. Combined with studies reporting activated microglia 
surrounding amyloid oligomers and senile plaques in acute and genetic rodent AD models 
[87], as well as in human brains [2], the data strongly suggests that TNF-α is chronically 
released during the course of AD, likely by activated microglia, neurons, and astrocytes 
stimulated by increased levels of extracellular Aβ [88].
Neurodegenerative disorders are associated with chronic central inflammation [73]. TNF-α 
increases the production of other pro-inflammatory cytokines, such as IL-1, IL-6, and IL-8 
[89], that can participate in the development of chronic inflammation when not counter-
balanced by anti-inflammatory cytokines (e.g. IL-10). Furthermore, TNF-α was shown to 
stimulate the expression of APP and BACE1 in primary cultures of mouse astrocytes, as well 
as stimulate γ-secretase activity in HEK cells, which results in the release of Aβ peptides in 
large amounts [70–72, 90]. Interestingly, a recent study indicated that rat neurons are 
differentially affected by TNF-α and Aβ42 during aging, with older neurons showing a 
decreased capacity to express TNF-α receptors than middle-aged neurons [91]. Collectively, 
the data suggests that, once chronic brain inflammation is engaged, a detrimental, auto-
amplified upward spiral maintains excessive levels of TNF-α, which could stimulate Aβ 
synthesis and neuronal loss, as well as inhibit microglia phagocytosis of Aβ [92]. Much less 
is known about the role of TNF-α in tau hyperphosphorylation and the molecular 
pathway(s) involved, though recent in vivo data suggests there may be a connection [93, 94].
3.2. TNF-α Single Nucleotide Polymorphism and Alzheimer’s Disease
The promoter region of the TNF-α gene bears several single nucleotide polymorphisms 
(SNPs). Of particular interest for AD, and other chronic disorders, is the mutation G308A 
(i.e. 308 bp prior to the start codon), which increases the expression of TNF-α mRNA and 
protein [95]. Careful experimentation revealed that the control of transcription does not 
occur via the regulation of transcription factors; instead it involves the generation of a high-
order of chromatin structure when G is at position −308, versus a low-order of chromatin 
structure that makes the region more accessible to transcription factors when the A mutation 
is present [96].
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Disease and meta-analyses studies reported that the frequency of the three possible −308 
mutation alleles in the general population are 70–80% (GG), 20–25% (GA), and 1–4% (AA) 
[97, 98]. Because of increased TNF-α expression with the A mutation, some authors 
suggested that this SNP could be linked with AD [99]. A recent meta-analysis did find, on 
one hand, a possible correlation between TNF-α G308A and the risk of AD in Chinese 
cohorts, but on the other hand reported a lower risk of suffering AD in northern European 
populations bearing this specific mutation [98]. Therefore, whether TNF-α G308A 
correlates with a higher probability of developing AD requires further investigation.
4. EVIDENCE THAT TNF-α MODULATION MAY SLOW OR PREVENT 
ALZHEIMER’S DISEASE
4.1. Evidence From Genetic Manipulations in AD Rodent Models
A large number of transgenic mouse and rat models have been generated to study AD. Those 
interested in such models are referred to recent reviews [100–102]. With regards to TNF-α 
signaling, there are a few lines of evidence from work on rodents support the idea of 
modulating TNF-α to manage AD progression. Genetic manipulations showed that altering 
TNF-α signaling reduces AD-like brain pathology in mice. For example, the deletion of 
TNF-RI gene in both APP23 (mimics Aβ pathology only; knock in of human APP bearing 
the Swedish mutation [sw; K595N/M596L] driven by the mouse Thy1.2 promoter [87]) and 
3xTg-AD (mimics both Aβ and tau pathologies; triple knock in of human presenilin-1 
mutated M146V driven by the presenilin 1 mouse promoter, and human APPsw and tau 
bearing the mutation P301L driven by the mouse Thy1.2 promoter [103]) mice resulted in 
decreased brain inflammation and Aβ burden [104, 105], while tau pathology was also 
reduced in 3xTg-AD mice which had their TNF-RI knocked out (TNF-RI−/−) [105]. Partial 
analysis of the mechanisms revealed a reduction in BACE1 expression in APP23 mice [104], 
confirming that TNF-α likely regulates brain BACE1 expression. In addition, McAlpine and 
collaborators [105] used the intra-ventricular delivery of a lentivirus to overexpress a 
dominant negative (DN) soluble isoform of TNF-α in 3xTg-AD mice. The competition of 
DN against endogenous TNF-α for receptor binding resulted in decreased brain amyloid 
burden [105], similar to the TNF-RI manipulations indicated above.
4.2. Pre-Clinical Pharmacological Evidence
4.2.1. Anti-TNF-α Biologics—Several anti-TNF-α antibodies and recombinant fusion 
proteins, often developed for rheumatoid arthritis or cancer treatment, have been tested on 
AD rodent models using both central and peripheral routes of administration. For instance, 
the acute intracerebral delivery of the anti-TNF-α antibody infliximab (150 µg) to 12 month-
old APP/PS1 mice (knock in of both human APPsw driven by the hamster prion protein 
promoter [mouse model Tg2576] and human presenilin-1 mutated M146V driven by the 
PDGF-β promoter [106]) induced a rapid and transient reduction in Aβ loads and tau 
phosphorylation [107]. The authors described the activation of brain immune cells in the 
process, though it is unclear whether these cells play a role in Aβ and tau clearance. In 
addition, the bio-engineered, anti-rheumatoid, anti-TNF-α fusion protein etanercept (TNF-
RII extracellular domain fused to IgG1 Fc) was administered subcutaneously (range 3–30 
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mg/kg) in an acute Aβ25–35-infused mouse model of AD. The peripheral administration of 
30 mg/kg etanercept resulted in improved cognitive outcome measures accompanied by 
reduced TNF-α levels in the hippocampus [108]. Whether etanercept is able to alter AD-like 
neuropathology in AD chronic models remains to be explored.
4.2.2. Anti-TNF-α Pharmacological Compounds—Anti-inflammatory drugs capable 
of altering TNF-α levels and NF-κB signaling after peripheral administration showed 
promise in treating brain pathology in AD-like mice.
4.2.2.1. Rapamycin: A low dose of the immunosuppressant rapamycin (2.24 mg/kg in food 
pellets) improved cognitive measures while reducing both amyloid and tau pathologies in 
3xTg-AD mice after 10 weeks of treatment [109]. This may be mediated by modulating the 
expression of pro-inflammatory cytokines during the blockage of T and B cell activation via 
the inhibition of mammalian target of rapamycin (mTOR) kinase (see section 5.9. below).
4.2.2.2. Minocycline: The antibiotic minocycline (∼55 mg/kg/day from food pellets for 3 
months) lowered Aβ burden and improved cognitive performance in middle-aged J20 mice 
(knock in of human APP bearing both the Swedish and Indiana mutations [ind; V717F] 
driven by the PDGF-β promoter) [110]. Although the exact molecular mechanisms regulated 
by minocycline in J20 mice were not reported, it was observed that minocycline is a 
neuroprotectant and might possess anti-inflammatory properties [111]. Similar positive 
effects on cognition were obtained when minocycline was administered intraperitoneally 
(i.p.; 45 mg/kg/day for three weeks) to an Aβ1-42-infused rat model and Tg2576 mice 
(knock in of human APPsw driven by the hamster prion protein promoter; 10 mg/kg/day 
minocycline, 5 days a week for 9 months) [112]. Importantly, minocycline (50 mg/kg/day) 
lowered brain inflammatory markers (COX-2, iNOS, and IL-1β), APP expression, and 
BACE1 activity when administered intraperitoneally for one month to young, pre-plaque 
McGill-Thy1-APP mice (knock in of human APPsw/ind driven by the murine Thy1.2 
promoter) [113]. However, in the latter study the authors reported liver and peritoneal 
toxicity, which “precluded the completion of behavioral testing for learning and memory” 
[113].
4.2.2.3. Thalidomide and Analogs: Compounds of the thalidomide family are referred to as 
immunomodulators and are known to reduce the half-life of TNF-α mRNA [114], thereby 
lowering TNF-α protein levels. Interestingly, thalidomide administered per orens to an 
Aβ1–40-infused mouse model (20 mg/kg/day thalidomide for two hours to three days after 
Aβ1–40 infusion) lowered hippocampal TNF-α mRNA levels, which translated to improved 
cognitive performance in an object recognition task carried out seven days after Aβ1–40 
infusion [115]. Test experiments conducted in our laboratory showed a 25% reduction in 
brain TNF-α protein levels in 12 month-old APP23 mice receiving thalidomide 100 
mg/kg/day via i.p. injections for three months (unpublished data). In addition, a recently 
developed analog, 3,6’-dithiothalidomide, at the dose of 50 mg/kg/day i.p. significantly 
reduced brain TNF-α mRNA and protein levels in 6 month-old 3xTg-AD mice (pre-plaque 
and tau pathologies), and this was accompanied by improved cognitive measures [116]. 
These studies showed the increased potency of 3,6’-dithiothalidomide compared to 
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thalidomide [116]. Furthermore, 3,6’-dithiothalidomide (42 mg/kg/daily. i.p. for 6 weeks) 
reduced Aβ loads and tau hyperphosphorylation, while improving cognitive performance in 
17 monthold 3xTg-AD mice [117]. In the latter study there had no demonstration that brain 
TNF-α levels were lowered in old 3xTg-AD mice, although complementary experiments 
suggest this. Further, the authors reported a significant down-regulation of the human 
APPsw transgene expression in old 3xTg-AD mice treated with the drug [117], concluding 
that “the possibility that some actions of 3,6′-dithiothalidomide may be mediated via 
suppression of this unnatural transgene promoter cannot be ruled out”. Complementary 
experiments using different AD mouse models could help solving this issue and ascertain 
that the compound reduces Aβ loads when a different promoter than Thy1.2 drives the 
expression of an hAPPsw transgene.
4.2.2.4. Celastrol: Celastrol is known for its antioxidant and anti-inflammatory properties, 
such as lowering of TNF-α and IL-1β expression in human monocytes and macrophages 
[118]. Recently, celastrol (1 mg/kg/day i.p. for four days) was reported to alter Aβ loads in 
PSAPP mice (knock in of both human APPsw driven by the hamster prion protein promoter 
[model Tg2576] and human presenilin-1 mutated M146V driven by the HMG-CoA 
reductase promoter [119]) [120].
4.2.2.5. NF-κB Modulation: As indicated in section 2.2 above, the binding of TNF-α to 
TNF-RI and TNF-RII triggers NF-κB signaling [42, 43, 48]. Consequently, most anti-TNF-
α drugs (including etanercept [121], infliximab [122], minocyclin [113], thalidomide [123], 
and celastrol [120]) were shown to reduce NF-κB phosphorylation (active state [48]) in 
various research models of inflammation. Interestingly, all these drugs reduced AD-like 
neuropathological features and, when assessed, improved cognitive measures (see references 
in sections 4.2.2.1–4 above).
4.2.2.6. Translation to Human Studies: Extrapolating pre-clinical pharmacological data to 
Phase I clinical trials involves deciding the starting drug dose to administer to human 
volunteers while ensuring their safety. The method recommended by the U.S. Food and 
Drug Administration (FDA) is the body surface area (BSA) normalization method [124]. 
This method calculates the quantity of drug per body surface area (e.g. mg/m2) rather than 
weight (e.g. mg/kg). While helpful, the BSA method does not necessarily correlate with the 
pharmacologically active dose. Thus, the FDA allows scaling to demonstrate therapeutic 
effect in human subjects using physiologic, pharmacokinetic, and toxicology data instead of 
the BSA method if scientifically supported (for recent discussion, see [125]).
4.3. Clinical Evidence
In addition to pre-clinical studies, two bodies of work in humans suggest that medications 
altering TNF-α signaling might prevent or lower AD neuropathology.
4.3.1. Non-Steroidal Anti-Inflammatory Drugs—The first agents are non-steroidal 
anti-inflammatory drugs (NSAIDs). Epidemiological studies indicate that some of these 
compounds, like ibuprofen, might help prevent AD-related cognitive decline if taken 
chronically by prodromal subjects [126]. However, clinical trials failed to detect cognitive 
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improvements in AD patients; thus it appears unlikely that NSAIDs alone are sufficient to 
treat AD after cognitive deficiencies develop [28].
4.3.2. Etanercept—Etanercept was reported to dramatically improve the condition and 
cognition of an AD patient after a single dose (25 mg) via perispinal administration [127]. 
Perispinal extrathecal administration is defined as the injection of molecules into the 
anatomic area within 10 cm of the spine (for etanercept, between the spinous processes of 
the C6 and C7 vertebrae) which contains numerous veins proposed to allow some transport 
into the brain via retrograde venous flow [128]. The chosen route of administration is due to 
etanercept’s large size (150 kDa) which prevents it crossing the BBB by passive diffusion 
[129]. Thus, this chimeric molecule must be delivered into the CNS for central inhibition of 
TNF-α. Further testing in 12 mild to moderate AD patients confirmed the potential of 
etanercept (25–50 mg weekly for 6 months) to slow AD-associated cognitive decline [130]. 
While encouraging, it is to note that results about etanercept on AD patients were collected 
during open-label trials without placebo controls, and the long-term effects on the sample 
population after drug wash out has not been reported. Moreover, a recent study using I-125-
labeled etanercept in rats did not demonstrate any penetration of the compound into the CNS 
after perispinal delivery [131], which contrasts with a previous study using the same 
paradigm [132]. Therefore, it is currently unclear whether the fast improvement of cognitive 
abilities recorded for etanercept in AD patients is due to a central or peripheral action of the 
drug, or possibly the placebo effect.
In summary, both animal and human studies suggest that modulating TNF-α synthesis 
and/or signaling may be viable therapeutic interventions to prevent or slow the progression 
of AD. Recent discussions argue that mouse models of AD recapitulate asymptomatic 
phases of the disease [133]. In addition, an increasing body of evidence suggest that 
neuroinflammation occurs at early stages of AD neuropathology (summarized in [134]). 
Taken together, pre-clinical and clinical data support the idea that anti-inflammatory 
strategies, including anti-TNF-α, might be more efficient when administered at early, or 
even at prodromal stages of AD, rather than at later stages of the disease. TNF-α inhibition 
strategies now need to be explored in clinical trials to confirm this hypothesis and assess 
tolerability and efficacy.
5. STRATEGIES AND CHALLENGES INVOLVING CENTRAL TNF-α 
SIGNALING MODULATION
Using the knowledge acquired in the past decades about the synthesis and 
physiopathological roles of TNF-α (see sections 2 and 3 above), physical and 
pharmacological interventions can be tested in clinical trials to modulate TNF-α levels or 
signaling, and to lower inflammation-driven AD neuropathology. In this section we present a 
non-exhaustive list of options and their limitations, which are summarized in Table 2.
5.1. Physical Exercise
In the past decade, a very interesting line of research has shown that physical exercise is able 
to reduce age-related low-grade inflammation (reviewed in [135, 136]). Several laboratories 
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reported that muscle contraction induces the synthesis and release of IL-6 from muscle cells 
during acute (single 2–4h long) exercises, as well as other cytokines which are referred to as 
myokines [137–140]. In addition, long-term (several weeks long) physical exercise lowered 
peripheral markers of inflammation in a small group of MCI patients (n=20) above 60 years 
of age and age-matched cognitively normal (CN) subjects (n=15) [141]. At baseline, both 
plasma IL-6 and TNF-α were elevated in MCI vs. control individuals (IL-6: 1.53 vs. 1.17 
pg/mL; TNF: 1.74 vs 1.48 pg/ml, respectively; p<0.05). After a 16 week period of 
multimodal exercise adapted to a population of this age range (see [142] for details), at the 
frequency of three weekly-one-hour-sessions, both plasma IL-6 and TNF-α levels dropped 
compared to baseline in the two cohorts (MCI IL-6: 1.36 vs 1.53 pg/L; MCI TNF: 1.49 vs. 
1.74; CN IL-6: 1.02 vs 1.17 pg/L; and CN TNF: 1.29 vs. 1.48; all values post- vs. pre-
exercise respectively; p<0.05) [141]. Furthermore, this chronic regimen of physical exercise 
improved cognition in active MCI patients vs. inactive, control MCI individuals [141], 
although it is not clear whether the benefit is solely the product of exercising or is combined 
with increased social interactions during exercise. While IL-6 is generally considered a 
proinflammatory cytokine, it may also act as an anti-inflammatory cytokine in human 
monocytic cells [143], likely via a post-transcriptional regulation mechanism [144], though 
the exact molecular mechanisms are unclear. Nonetheless, if these findings are confirmed, 
such therapeutic intervention might be safer to administer to large scale populations than 
some of the pharmacological agents described below. Therefore, the potential benefits might 
warrant broader experimentation, although attrition is often recorded in trials involving long-
term physical exercise (e.g. [145]) and such trials are open-label rather than double-blind.
5.2. IL-6 Supplementation
Since physical exercise may induce the release of IL-6 from muscle cells into the blood, one 
could ask whether the administration of IL-6 alone is sufficient to reduce peripheral TNF-α 
levels. Starkie and collaborators infused physiological levels (dose not described) of 
recombinant human IL-6 (rhIL-6) for 3h to a small group of healthy subjects [139]. The 
authors recorded a drop in plasma TNF-α levels in a manner similar to physical exercise 
[139]. In addition, they observed that pre-infusion of rhIL-6 blocks the induction of TNF-α 
production following acute administration of endotoxin, again very similar to the effect of 
physical exercise. The authors concluded that administering rhIL-6 or physical exercise 
produce an anti-inflammatory effect that has the potential to reduce low-grade-inflammation 
[139].
Interestingly, another group showed that both IL-6 and IL-10 reduce TNF-α expression in 
primary rat astrocytes via regulation of translation [146]. Furthermore experimentation in 
healthy humans revealed that an acute arterial infusion of rhIL-6 (30 µg/h for 3h) induces a 
transient increase in plasma anti-inflammatory cytokines IL-1 receptor antagonist (IL-1ra) 
and IL-10 [147], paralleling results obtained in subjects who completed a marathon race 
[140]. Surprisingly, plasma TNF-α levels remained unchanged during and after rhIL-6 
infusion. Importantly, however, both blood cortisol levels and the number of circulating 
neutrophils increased during rhIL-6 infusion [147]. This is of great importance for TNF-α 
modulation because 1- corticoids are inhibitors of TNF-α synthesis (see section 5.7 below); 
and 2- activated neutrophils release pro-inflammatory cyctokines, incuding TNF-α, which 
Decourt et al. Page 10
Curr Alzheimer Res. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
facilitate extravasation through the endothelium (including in the BBB) and increase the 
levels of cytokines in tissues [148], but cortisol alters the binding of neutrophils to the 
endothelial membrane and prevents infiltration and release of cytokines into tissues [149]. 
Thus, treatment of patients with rhIL-6 appears to be a possible therapeutic intervention, for 
example for subjects with limited physical abilities such as after amputation or when 
suffering joint diseases. However, we did not find any literature about the long-term effect of 
IL-6 supplementation on inflammatory markers. Consequently, we believe that caution 
should be exerted before treating large AD cohorts since high levels of IL-6 were reported to 
correlate with increased risks of metabolic and immune diseases, such as coronary heart 
diseases [150, 151], and diabetes [152], though it is unclear whether IL-6 causes these 
diseases or is released by the body to prevent them.
5.3. Acetylcholinesterase Inhibitors and Nicotine
Acetylcholine (ACh) is one of the major neurotransmitters affected by AD. But, beside its 
role at the synaptic level in the brain, in recent years it was shown that ACh also modulates 
inflammation via what is referred to as the “immune cholinergic system” [153]. The system 
works thanks to lymphocytes and monocytes possessing the enzymatic machinery to 
synthesize (Choline acetyltransferase; ChAT) and degrade (Acetylcholinesterase; AChE) 
ACh. Activation of these immune cells leads to increased expression of ChAT and synthesis 
of ACh. After release, ACh can bind muscarinic and nicotinic receptors located on effector 
cells, which lowers the production of pro-inflammatory cytokines. The effects of ACh were 
mimicked by infusion of macrophages with nicotine (1–100 µM range), but not muscarine 
(1–100 µM range) [154]. Interestingly, both macrophages and microglia were shown to 
express the α7 subunit of the nicotinic receptor (α7 nAChR) [155]. This particular subunit 
was demonstrated to downregulate the NF-κB-mediated transcription of pro-inflammatory 
cytokines (summarized in [156]).
Of particular interest for AD, Aβ was shown to increase the activity of AChE in a 
neuroblastoma cell line, likely by slowing down the degradation of this enzyme rather than 
increasing its synthesis [157]. Similarly, challenging human THP-1 and peripheral blood 
mononuclear cells with Aβ induced the synthesis of pro-inflammatory cytokines, including 
TNF-α [158]. This increase was mitigated by infusing the cells with AChE inhibitors [158]. 
Furthermore, it was recently shown that anti-ACh drugs exacerbate systemic inflammation 
in a mouse model of tauopathy [93], though the exact molecular mechanisms remain to 
investigate. In addition, the acute administration of the AChE inhibitor galantamine (1–4 
mg/kg i.p.) 1h prior to endotoxin (6 mg i.p.) in mice significantly reduced TNF-α serum 
levels, and this process required normal signaling by the vagus nerve [159]. Taken together, 
the data suggests that a systemic reduction in ACh may drive chronic inflammation by 
stimulating the production of pro-inflammatory cytokines, which could be modulated by 
AChE inhibitors. AChE inhibitors are one of the few FDA-approved drugs for AD treatment 
to date. Given their potential on the immune cholinergic system, it is possible that their 
transient slowing down of AD symptoms is mediated not only by central neurotransmission 
regulation, but also by affecting peripheral and central inflammation. However, it is well 
known that the effect of AChE inhibitors is short in duration (several months only), 
suggesting that this approach alone is not sufficient to counteract AD-related inflammation 
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after symptoms appear, and additional therapeutic interventions are likely required to 
produce lasting effects.
5.4. Etanercept
Following the positive outcome of etanercept perispinal administrations on cognitive 
performance in AD subjects in small scale studies (see section 4.3 above), this biologic 
could be tested on a larger sample population, in a randomized, double-blind, placebo-
controlled study, to confirm the original findings. Since it is not clear whether perispinal 
administration carries etanercept into the CNS [131], while TNF-α is transported across the 
BBB (as explained in section 2 above), it is possible that altering peripheral TNF-α might 
lower its brain levels since less TNF-α would cross the BBB.
Interestingly, the subcutaneous administration of etanercept in an acute murine model of AD 
(30 mg/kg) improved cognitive measures and lowered TNF-α levels in the hippocampus 
[108] (section 4.2 above). This approach was then translated into a double-blind, 
randomized clinical trial on 41 mild to moderate AD patients receiving etanercept (n=20) 
and placebo control (n=21). The study reported that weekly subcutaneous injections of 
etanercept (50 mg for 24 weeks) was well tolerated in AD patients whose main adverse 
events were increased, but manageable infections [160]. However, compared to placebo 
controls, no significant amelioration in cognitive outcomes and daily activities were 
demonstrated in patients treated with etanercept [160]. The authors concluded that 
increasing the number of patients might be needed to obtain significant improvement of 
cognitive performance.
Since inflammation exacerbates AD neuropathological features, which build up during the 
pre-symptomatic phase of the disease [134, 161], we suggest that clinical trials targeting 
inflammatory molecules and pathways should recruit patients suffering mild cognitive 
impairment (MCI) to early AD to try preventing further neuronal death rather than treating 
patients at mild to moderate stages who already suffer significant neuronal loss. But caution 
is required for long term administration of etanercept because psychiatric adverse events, 
such as schizophrenia-like disorders [162], have been reported, indicating that some patients 
may require close monitoring. Nonetheless, if the peripheral administration of etanercept 
proves effective to slow AD progression, then peripheral administration of other biologics, 
such as anti-TNF-α and anti-TNFRI antibodies, could also be tested in the future.
5.5. Anti-TNF-α Antibodies
Another option to capture soluble TNF-α and prevent its binding and activation of cellular 
receptors is to use highly specific, bioengineered anti-TNF-α antibodies such as infliximab 
and adalimumab [163]. Infliximab was administered intracerebroventricularly (150 µg daily 
injection for three days) to the AD mouse model APP/PS1 at 12 months of age, i.e. when 
brain pathology is established. The authors reported a rapid reduction in brain TNF-α, Aβ, 
and tau phosphorylation levels, which were accompanied by an activation of monocytic 
CD11c-positive cells [107]. However, no cognitive data were provided. On a cautious note, 
adverse events have been reported in patients treated with anti-TNF-α antibodies for 
rheumatoid arthritis, including lymphoma, neuropathies, and infections [164]. In addition, 
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like etanercept [129] most antibodies show very limited crossing of the BBB via passive 
diffusion [165], thus they must be administered either centrally to efficiently inhibit CNS 
TNF-α, or in the periphery to lower circulating TNF-α and its crossing of the BBB. In 
addition, the ability of anti-TNF-α antibodies, administered peripherally, to reduce central 
TNF-α and AD-like neuropathology in rodent models has not been reported yet.
5.6. Anti-TNFRI Antibodies
As an alternative to capturing sTNF-α, TNF-α signaling could be reduced by antagonizing 
its receptors. As indicated in section 3.4. above, TNF-RI is mostly pro-apoptotic. The 
genetic deletion of this receptor showed improvement in AD-like pathology in rodent 
models (see section 4.1 above). For clinical applications, an anti-TNF-RI antibody has been 
bioengineered with a modified Fc region and named ATRO-SAB. Although no data are 
currently available on its effects on AD pathology, its in vitro bioactivity showed blockage 
of TNF-α-induced expression of IL-6 and IL-8 in HeLa cells via reduction of NF-κB 
activation [166]. In addition, the authors showed that the classical pathway of activation of 
the complement system was not activated by this antibody, indicating that once it binds to 
the cell surface it does not stimulate opsonization and cell lysis. Like for etanercept and anti-
TNF-α antibodies, inhibition of CNS-located TNF-RI would likely require central 
administration given the low rate at which antibodies penetrate the brain parenchyma by 
passive diffusion through the BBB [165]. Furthermore, additional testing is required to 
determine whether peripheral administration of ATROSAB could reduce AD-like 
neuropathology and cognitive impairment in rodent models. Finally, the toxicity profile of 
this antibody will need to be assessed in Phase I studies before planning Phase II clinical 
trials on AD cohorts.
5.7. Corticoids
Corticoids are well known general inhibitors of inflammation used in many pathological 
conditions such as asthma and skin rashes. Mechanistically, corticoids are plasma 
membrane-soluble molecules that bind cytoplasmic glucocorticoid receptors (GR), inducing 
their nuclear translocation (summarized in [167]). Once in the nucleus, the corticoid-GR 
complex can either bind DNA glucorticoid response elements (GRE) to increase the 
transcription of anti-inflammatory cytokines (e.g. IL-10), or regulate other transcription 
factors, including depressing the NF-κB-driven transcription of pro-inflammatory cytokines. 
It is also proposed that corticoids may destabilize some pro-inflammatory mRNAs, though 
the exact mechanisms are unclear [167]. At the cellular level, corticoids prevent the 
attachment of neutrophils to endothelial cells, which reduces the extravasation of these cells 
and build up of cytokines in tissues [148]. Pilot experiments were conducted with 
dexamethasone (10 µM) on LPS-challenged whole blood samples from AD patients and 
healthy subjects. The authors reported that dexamethasone was more efficient on AD 
samples vs. controls [168]. Interestingly, dexamethasone is commonly co-administered with 
thalidomide analogs in cancer treatment (see section 5.8 below) because a cumulative effect 
on inflammation reduction was noted during clinical trials. However, long term 
administration of corticoids often results in adverse events such as increased risks of 
infection, osteoporosis, and mental depression via alteration of the hypothalamic-
Decourt et al. Page 13
Curr Alzheimer Res. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
pituitaryadrenal (HPA) axis [168, 169], limiting their potential to treat chronic disorders like 
AD.
5.8. Thalidomide and Analogs
Because AD is a complex disease [161], the use of pleiotropic anti-inflammatory agents may 
be required to not only reduce pro-inflammatory, but also increase anti-inflammatory 
cytokines. Examples of this pharmacological class include immunomodulators of the 
thalidomide family which are very potent TNF-α inhibitors, and which were proposed as 
therapeutic agents for neurodegenerative disorders [31, 170]. Their mechanism of action is 
via destabilization of TNF-α mRNA, which reduces protein synthesis [114] , but they also 
modulate other cytokines [171]. In a separate paper in this special edition of CAR, we report 
the testing of thalidomide in mild-to-moderate AD patients (see Thalidomide paper in this 
special edition). Our main conclusion is that the toxicity of thalidomide unfortunately 
induced too many adverse events (including somnolence, constipation, and peripheral 
neuropathy), which resulted in participants prematurely withdrawing from the study. In 
addition, and as indicated above, inflammation exacerbates AD neuropathological features 
and is detected at early stages of AD [172]. Since our sample population consisted of mild to 
moderate AD patients, our study design was likely not optimal to detect the preventive 
effects of thalidomide.
Interestingly, several novel thalidomide analogs generated recently have been shown to be 
potent TNF-α synthesis inhibitors in vitro [173, 174]. For example, the thio-modified 
compound 3,6’-dithiothalidomide lowered the synthesis of inflammatory markers in the 
mouse macrophagic cell line RAW 264.7, and in rat blood after LPS stimulation [117]. Of 
interest for AD research, the drug was also shown to improve cognitive measures and 
reduced Aβ loads in 3xTg-AD mice [117]. Thus, we suggest that future trials testing the 
potential of less toxic thalidomide analogs should focus on MCI to early AD cohorts in the 
hope of preventing further accumulation of neuropathological features and cognitive decline, 
rather than testing such compounds as disease-modifying therapies in mild- to late-AD 
patients who suffer advanced cognitive deficits.
5.9. Immunosuppressants
In this section we refer to immunosuppressive drugs known as anti-rejection medications, 
which inhibit B and T cells activation. The major compounds of this class are the cyclic 
undecapeptide cyclosporine, the macrolide antibiotic tacrolimus, and the antifungal 
rapamycin [175]. They are used mostly to 1- prevent the rejection of transplanted organs and 
tissues; 2- treat autoimmune diseases (e.g., rheumatoid arthritis, multiple sclerosis, 
myasthenia gravis, systemic lupus erythematosus); and 3- treat some non-autoimmune 
inflammatory diseases (e.g. long-term allergic asthma).
Cyclosporine and tacrolimus (also named FK-506) are both inhibitors of the calcium/
calmodulin dependent serine/threonine protein phosphatase calcineurin. Cyclosporine A 
binds to proteins located in the cytoplasm of immunocompetent lymphocytes called 
cyclophilins. Tacrolimus binds to FK-506 binding proteins (FKBP) [176]. The drug-protein 
complexes then bind calcineurin to inhibit the dephosphorylation (activation) of the 
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transcription factor, nuclear factor of activated T cell, cytoplasmic (NFATc). This results in 
the blockage of T cell activation, and altered expression of the pro-inflammatory cytokine 
IL-2, which prevents further activation of cell-activated immunity that is characterized by 
the release of TNF-α [177]. Both cyclosporine (50 µM) and tacrolimus (50 µM) were shown 
to downregulate the expression of APP mRNA and protein in primary cultures of neonatal 
rat astrocytes [178]. However, we did not find any report on clinical trials for AD. To note, 
while cyclosporine and tacrolimus are very potent anti-inflammatory drugs, cyclosporin does 
not cross the BBB because it is endocytosed and then trapped in the cerebral endothelial 
cells [179], and long term treatment with high doses often results in nephrotoxicity, and 
occasionally in neurotoxicity [180, 181].
Rapamycin (also named sirolimus) binds to FKBP, and then inhibits the serine/threonine 
kinase mTOR Complex 1. Contrary to cyclosporine A and tacrolimus which affects the first 
phase of T lymphocyte activation, rapamycin affects the second phase, i.e. signal 
transduction and lymphocyte clonal proliferation, preventing their transition from G1 to S 
phase of the cell cycle [182]. In addition, rapamycin prevents B cell differentiation to plasma 
cells, reducing the production of IgM, IgG, and IgA antibodies [183]. Oddo and 
collaborators showed that rapamycin reduces both Aβ and tau pathologies while improving 
cognitive measures in 3xTg-AD mice [109]. Whether rapamycin could be effective on AD 
patients remains to be tested in clinical trials, though chronic administration may generate 
adverse events such as diabetes, thrombocytopenia, anemia and leucopenia [184].
5.10. Stimulation of Repressors of Transcription
Recently, novel endogenous proteins have been identified which inhibit the transcription of 
TNF-α. One of these molecules is the Leucine-rich repeat in Flightless-1 interaction protein 
1 (GCF2/LRRFIP1). Initial investigations have shown that GCF2/LRRFIP1 occupies the 
region −308 of the TNF-α gene promoter [185]. Very interestingly, GCF2/LRRFIP1 seems 
to act as a transcription inhibitor that completely represses TNF-α transcription in cells that 
do not express this cytokine physiologically [185]. A very recent report showed that GCF2/
LRRFIP1 regulates pro-survival proteins and pathways in rat astrocytes, including β-catenin, 
Akt, and mTOR [186]. While still at early stages of investigation, if the effects of GCF2/
LRRFIP1 are confirmed, it could become a new therapeutic target to modulate TNF-α 
expression, although its negative effects must also be studied as another report suggests it 
may stimulate metastasis in some forms of cancers [187].
5.11. Potential Health Hazards
Finally, as reported in the etanercept clinical trial [188], inhibiting TNF-α in a chronic 
manner might reduce the potential of AD patients to fight infections and cancers. 
Furthermore, the complete deletion of TNF-α receptors (TNF-RI and II) in 3xTg-AD mice 
resulted in exacerbated AD-like neuropathology, suggesting that pan-TNF-α suppressive 
therapeutic strategies might be detrimental rather than beneficial for AD treatment [189]. 
Moreover, a few neurological adverse events associated with anti-TNF-α agents were 
reported, which include central and peripheral demyelination, CNS lupus, encephalitis, and 
polyneuropathies [181, 190–192]. Therefore, we advocate that all clinical trials using TNF-α 
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inhibitors on AD patients include a pharmacovigilance section to monitor possible 
neurological adverse events.
CONCLUSION
Chronic central inflammation plays a major role in the development of AD neuropathology 
and associated dementia. Therefore, developing therapeutic interventions to modulate 
inflammation represents a valid option to treat AD. Because of its pivotal role in 
inflammation, TNF-α is a very attractive pharmacological target. In addition, pre-clinical 
data indicate that increased TNF-α levels exacerbates amyloidogenesis, and diverse 
paradigms used to reduce TNF-α signaling in rodent models of AD showed significant 
reduction in AD-like brain pathology accompanied by an amelioration of cognitive function. 
Therefore, TNF-α inhibition to prevent or slow AD should be explored in more depth in 
clinical trials. However, we recommend that the inhibition of TNF-α be kept to mild to 
moderate levels in order not to induce adverse events resulting from blocking the 
physiological roles of TNF-α in the CNS (Table 1).
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Table 1
Physiological and deleterious effect of TNF-α signaling in the CNS.
TNF-α Function References
Neurophysiology (basal expression and acute disease state)
- Development: act as a neurotrophic factor (neuronal apoptosis) [32]
- Development: facilitate cell migration and proliferation [58]
- Cognition [59, 60]
- Synaptic plasticity [58, 61]
- Astrocytic gliotransmission [58]
- Ionic homeostasis [62]
- Protects from excitotoxicity [63]
- Facilitator of remyelination by promoting oligodendrocyte survival [64]
- Sleep [65]
- Food and water intake [66]
- Anti-neurogenic effect during adult neurogenesis (cultured ippocampal progenitor cells and SVZ progenitor cells) [67, 68]
- Host defense [69]
- Restore brain homeostasis and functions during acute inflammation [34, 45]
Neuropathology (chronic expression in moderate to high amounts)
- Promote excitotoxicity (in association with glutamate) [63]
- Cause synaptic loss [58, 61,63]
- Stimulate astrogliosis and microgliosis [57]
- Exacerbate amyloidogenesis in Alzheimer’s disease [70–72]
- Participate in multiple sclerosis, amyotrophic lateral sclerosis, Parkinson’s disease, ischemia, and other neurological 
disorders
[32, 34, 73–75]
- Drive HIV-associated dementia [76]
Curr Alzheimer Res. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Decourt et al. Page 28
Table 2
Possible therapeutic interventions to decrease TNF-α signaling in AD, their targeted mechanism of action, and 
potential health hazards. See text in Section 5. for details and references.
Possible Therapeutic Intervention Mechanism of action Potential Limitations
Physical exercise Muscle contraction induces the release of IL-6
that seems to act as TNF-α inhibitor
None
IL-6 supplementation Acute IL-6 supplement alone seems to reduce
peripheral TNF-αlevels, and increase IL-1ra, 
IL-10
and cortisol
IL-6 is an ambivalent cytokine that could 
induce
other severe conditions upon chronic 
administration
Acetylcholinesterase inhibitors and 
nicotine
Activation of α7 nicotinic acetyl choline 
receptors
which regulate cytokine transcription via
NF-κB modulation
AChE inhibitors used currently to treat AD 
have
limited time effects, showing this option alone 
is
not viable for long term treatment
Etanercept Capture of soluble TNF-α blocking it from
binding cellular receptors
Do not cross the BBB; central administration 
is
high risk
Anti-TNF-α antibodies (e.g. Infliximab) Capture of soluble TNF-α blocking it from
binding cellular receptors
Do not cross the BBB; central administration 
is
high risk
Anti-TNF-RI antibodies Competes against TNF-α to bind TNF-RI, but
does not activate signal transduction
Do not cross the BBB; central administration 
is
high risk
Corticoids (e.g. dexamethasone) General inhibitors of inflammation via 
regulation
of NF-κB by glucocorticoid receptors; may also
destabilize mRNAs
Chronic administration may induce
endocrine-related pathologies via 
disregulation of the
hypothalamic-pituitary-adrenal axis
Thalidomide and analogs Destabilize TNF-α mRNA; modulate cytokines,
chemokines, and NF-κB
Commercially available thalidomide analogs
induce neutropenia, thrombocytopenia, and 
various
adverse events
Immunosuppressants (e.g. cyclosporine, 
rapamycin)
General inhibitors of the immune response by
inhibiting T and B cells activation
Chronic immunosuppression increases the 
risk of
infection, neutropenia, and thrombocytopenia
Stimulation of repressors of transcription 
(e.g.
GCF2/LRRFIP1)
Binding of TNF-α promoter region to repress
transcription
May repress other genes than TNF-α leading 
to
adverse events and/or other pathologies
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